newsfilter
← Latest News
GlobeNewswire·

Tiziana Life Sciences to Present at BIO-Europe 2026 and Host KOL Webcast

  • Tiziana Life Sciences (Nasdaq: TLSA) announced it will present at BIO-Europe 2026 in Cologne, Germany, from November 9–11, 2026.
  • The company hosted a conference call & webcast with Key Opinion Leaders on November 9, 2026, to discuss positive topline results from the Phase 2a INFORM-MS trial of intranasal foralumab in na-SPMS.
  • CEO Ivor Elrifi delivered a presentation on November 10, 2026, within the Presenting Companies track at BIO-Europe.
  • Management & business development teams attended BIO-Europe to engage in one-to-one partnering meetings with potential investors, partners, & collaborators regarding the INFORM-MS results & broader pipeline.
  • The pipeline includes intranasal foralumab for Alzheimer's disease, multiple system atrophy (MSA), & amyotrophic lateral sclerosis (ALS) in addition to na-SPMS.
  • Foralumab is a fully human anti-CD3 monoclonal antibody that stimulates T regulatory cells when dosed intranasally.
  • An open-label intermediate-sized Expanded Access Program has dosed 14 na-SPMS patients, showing improvement or stability in all patients within 6 months.
  • Intranasal foralumab is the only fully human anti-CD3 monoclonal antibody currently in clinical development.
  • Tiziana Life Sciences utilizes transformational drug delivery technologies to enable alternative immunotherapy routes, potentially offering improved efficacy, safety, & tolerability compared to intravenous delivery.